Sentence examples for mg at baseline from inspiring English sources

In this multicenter, randomized, double-blind, placebo-controlled study, patients with EM were randomized 1 1 1 to receive subcutaneous injections of fremanezumab quarterly (675 mg at baseline and placebo at Weeks 4 and 8), fremanezumab monthly (225 mg at baseline, Weeks 4 and 8), or placebo at each time point over a 12-week treatment period.

In this multicenter, randomized, double-blind, placebo-controlled study, patients with CM were randomized 1 1 1 to receive subcutaneous injections of fremanezumab quarterly dosing (675 mg at baseline and placebo at Weeks 4 and 8), fremanezumab monthly dosing (675 mg at baseline and 225 mg at Weeks 4 and 8), or placebo at each time point over a 12-week treatment period.

In this multicenter, randomized, double-blind, placebo-controlled, Phase III study, eligible patients with CM were randomized 1 1 1 to receive subcutaneous injections of fremanezumab quarterly dosing (675 mg at baseline and placebo at Weeks 4 and 8), fremanezumab monthly dosing (675 mg at baseline and 225 mg at Weeks 4 and 8), or placebo at each time point over a 12-week treatment period.

Mean VIU uptake per lesion was 4.3 mg at baseline (SD ±4 mg).

The mean daily levodopa dose in the CLE group was lower by 24.6 mg (from 509 mg at baseline).

All the participants were tested for MG at baseline, six months and 12 months throughout the study period.

The median M of placebo group was 8.4 mg min−1 lbm−1 at baseline and 9.3 mg min−1 lbm−1 after 6 months and the median difference was −0.22 mg min−1 lbmin−1n=17).

However, d-xylose urinary excretion, reflecting distal duodenal absorption function, increased in seven of eight participants with an overall increase from a median of 33.8 mg (28.7 38.2) at baseline to 40.9 mg (19.8 44.4) at week 7 (P = 0.19; Fig. 3b) [5].

Plasma hs-CRP concentrations decreased significantly from a median value of 0.49 mg l−1 at baseline (interquartile range, 0.26 0.87) to 0.37 mg l−1 (0.23–0.79) at 6 months (P < 0.05), an effect that was independent of changes in serum lipids [61].

261 patients who received an injection of 405 mg OLAI at baseline followed by individual dosing of 150 mg to 405 mg/4 weeks were included in the analysis [ 7].

Efficacy in those patients who crossed over to the treatment group at week 20 to receive one 90 mg dose mirrored the improvements observed in individuals originally assigned to the one 90 mg dose at baseline.